New tool helps sarcoma patients weigh treatment risks and benefits

NCT ID NCT05741944

First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 26 times

Summary

This study looks at whether a personalized risk assessment tool called PERSARC can help patients with soft-tissue sarcoma make better-informed treatment decisions. About 120 adults with high-grade sarcoma in their arms or legs will either receive standard care or use PERSARC to understand their risks and options. The goal is to reduce confusion and regret when choosing treatments.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOFT TISSUE SARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Erasmus MC

    Rotterdam, South Holland, 3015GD, Netherlands

  • Leiden University Medical Center

    Leiden, South Holland, 2333ZA, Netherlands

  • Maastricht UMC

    Maastricht, Limburg, 6229HX, Netherlands

  • Netherlands Cancer Institue

    Amsterdam, North Holland, 1066CX, Netherlands

  • Radboud UMC

    Nijmegen, Gelderland, 6525GA, Netherlands

  • UMC Groningen

    Groningen, Provincie Groningen, 9713GZ, Netherlands

  • UMC Utrecht

    Utrecht, Utrecht, 3584CX, Netherlands

Conditions

Explore the condition pages connected to this study.